| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | 177,260 | VSTM, EOLS, TENX, NKTR | RESTATEMENT | 8/17/2026 | 000144077126000016 |
| Q1 2026 | 83 | 249,722 | XBI puts, XBI calls, VSTM, TENX | 13F-HR | 5/14/2026 | 000144077126000002 |
| Q4 2025 | 66 | 136,970 | VSTM, ADMA, EOLS, ZVRA | 13F-HR | 2/13/2026 | 000093583626000090 |
| Q3 2025 | 58 | 123,007 | VSTM, ADMA, EOLS, ZVRA | 13F-HR | 11/13/2025 | 000093583625000666 |
| Q2 2025 | 59 | 101,927 | ADMA, EOLS, ZVRA, VSTM | 13F-HR | 8/13/2025 | 000093583625000497 |
| Q1 2025 | 66 | 102,762 | ANIP, EOLS, OPTN, ZVRA | 13F-HR | 5/14/2025 | 000093583625000328 |
| Q4 2024 | 52 | 123,887 | ADMA, EOLS, TELA, LKFT | 13F-HR | 2/13/2025 | 000093583625000151 |
| Q3 2024 | 38 | 158,247 | ADMA, EOLS, LKFT, JAZZ | 13F-HR | 11/13/2024 | 000093583624000663 |
| Q2 2024 | 25 | 109,604 | ADMA, ALIM, EOLS, LKFT | RESTATEMENT | 8/20/2024 | 000093583624000540 |
| Q1 2024 | 20 | 126,057 | EOLS, ADMA, ALIM, LKFT | 13F-HR | 5/14/2024 | 000093583624000386 |
| Q4 2023 | 16 | 231,228 | EOLS, ADMA, AMLX, QDEL | 13F-HR | 2/13/2024 | 000093583624000133 |
| Q3 2023 | 23 | 301,032 | QDEL, EOLS, AMLX, ADMA | 13F-HR | 11/13/2023 | 000093583623000688 |
| Q2 2023 | 2 | 11,032 | XFOR, DCTH | NEW HOLDINGS | 8/16/2023 | 000093583623000589 |
| Q2 2023 | 19 | 266,194 | QDEL, EOLS, ADMA, LKFT | 13F-HR | 8/11/2023 | 000093583623000564 |
| Q1 2023 | 22 | 298,170 | AMYT, LKFT, CTIC, ADMA | 13F-HR | 5/12/2023 | 000093583623000397 |
| Q4 2022 | 19 | 237,711 | AMYT, APEN, CTIC, ADMA | 13F-HR | 2/14/2023 | 000093583623000233 |
| Q3 2022 | 19 | 222,441 | AMYT, QDEL, CTIC, XERS | 13F-HR | 11/10/2022 | 000156761922019570 |
| Q2 2022 | 25 | 214,932 | AMYT, CTIC, XERS, ADMA | 13F-HR | 8/12/2022 | 000156761922015877 |
| Q1 2022 | 28 | 241,108 | AMYT, CTIC, XERS, AMRN | 13F-HR | 5/16/2022 | 000156761922010659 |
| Q4 2021 | 23 | 217,913 | AMYT, CTIC, XERS, ADMA | 13F-HR | 2/14/2022 | 000156761922003693 |
| Q3 2021 | 31 | 219,763 | AMYT, CTIC, ADMS, LKFT | 13F-HR | 11/12/2021 | 000156761921020046 |
| Q2 2021 | 26 | 191,224 | AMYT, CHMA, CTIC, ADMS | RESTATEMENT | 8/16/2021 | 000156761921015565 |
| Q1 2021 | 29 | 185,124 | AMYT, ADMS, CHMA, CBIO | 13F-HR | 5/14/2021 | 000156761921010194 |
| Q4 2020 | 21 | 130,625 | LGND, AMYT, DMAC, AYTU | 13F-HR | 2/12/2021 | 000156761921003590 |
| Q3 2020 | 17 | 96,131 | LGND, ISEE, AMYT, CTIC | 13F-HR | 11/13/2020 | 000156761920019541 |
| Q2 2020 | 13 | 51,630 | ISEE, LGND, CTIC, DMAC | 13F-HR | 8/13/2020 | 000156761920015104 |
| Q1 2020 | 27 | 94,557 | LGND, ISEE, CTIC, AMRN | 13F-HR | 5/14/2020 | 000156761920010136 |
| Q4 2019 | 23 | 143,457 | AMRN, ISEE, AFMD, OXFD | 13F-HR | 2/13/2020 | 000156761920003323 |
| Q3 2019 | 26 | 103,032 | AMRN, OXFD, BDSI, ENTA | 13F-HR | 11/13/2019 | 000156761919021211 |
| Q2 2019 | 25 | 145,241 | LGND, VNDA, AMRN, BDSI | 13F-HR | 8/13/2019 | 000156761919016550 |
| Q1 2019 | 30 | 173,855 | VNDA, AMRN, LGND, NEOS | 13F-HR | 5/14/2019 | 000156761919010831 |
| Q4 2018 | 22 | 113,865 | AMRN, BDSI, BSTC, CPIX | 13F-HR | 2/13/2019 | 000156761919003836 |
| Q3 2018 | 31 | 171,016 | AMRN, APEN, BSTC, BDSI | RESTATEMENT | 11/28/2018 | 000156761918007015 |
| Q2 2018 | 25 | 164,570 | BSTC, CTIC, APEN, AMRN | 13F-HR | 8/14/2018 | 000156761918000669 |
| Q1 2018 | 30 | 186,623 | BSTC, CTIC, AMRN, VNDA | 13F-HR | 5/14/2018 | 000114036118023316 |
| Q4 2017 | 27 | 166,847 | VIVE, BSTC, APEN, VNDA | 13F-HR | 2/13/2018 | 000114036118007210 |
| Q3 2017 | 22 | 169,648 | VIVE, ENTA, PCRX, SCTL | 13F-HR | 11/13/2017 | 000114036117042192 |
| Q2 2017 | 27 | 185,191 | VIVE, ENTA, NVLNF, SCTL | 13F-HR | 8/14/2017 | 000114036117031650 |
| Q1 2017 | 21 | 177,452 | SCTL, VIVE, NVLNF, SCLN | 13F-HR | 5/12/2017 | 000114036117020108 |
| Q4 2016 | 23 | 167,888 | SCTL, Aegerion Pharmaceuticals, Inc., ALR, SCLN | 13F-HR | 2/10/2017 | 000114036117005766 |
| Q3 2016 | 17 | 122,629 | TBRA, VIVE, Aegerion Pharmaceuticals, Inc., ALR | 13F-HR | 11/14/2016 | 000114036116086160 |
| Q2 2016 | 23 | 97,537 | SCLN, Viveve Medical, Inc, Aegerion Pharmaceuticals, Inc. (NOTES), VNDA | RESTATEMENT | 8/11/2016 | 000114036116075782 |
| Q1 2016 | 19 | 84,794 | SCLN, VNDA, VCEL, PTIE | 13F-HR | 5/11/2016 | 000114036116064477 |
| Q4 2015 | 13 | 85,361 | VNDA, CTIC, SCLN, TBRA | 13F-HR | 2/11/2016 | 000114036116051710 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G.
22 securities where the latest filing since 12/18/2024 is a 13G, the newest filed 8/31/2026. View all